pakistan
Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
Key takeaways
- As many patients struggle with declining insurance coverage, the lower-priced options have been a boon for the drugmakers, the doctors said.
- Denmark’s Novo and Indianapolis-based Lilly began selling the oral medications in the U.S. in January and April, respectively, and have boasted of strong demand from new patients.
- Still, they have complained about compounded versions, which are allowed by the U.S.
Why this matters: local context for readers following news across Pakistan and the region.
Add ARY News on Google AAResize Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U.S. doctors.
Prices for the lowest doses of both Novo’s oral Wegovy and Lilly’s Foundayo tend to be lower than for their injected obesity medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions.
As many patients struggle with declining insurance coverage, the lower-priced options have been a boon for the drugmakers, the doctors said.
Article preview — originally published by ARY News. Full story at the source.
Read full story on ARY News →
More top stories
Also covered by
Aggregated and edited by the Scoop newsroom. We surface news from ARY News alongside other reporting so you can compare coverage in one place.
Editorial policy · Corrections · About Scoop